Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.
In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs. Here, we will give a short insight into our published results.
Enrolment
| Eingeschlossene Patienten: 19.247 (Stand 04. Februar 2020) | |
|---|---|
| Amgevita® (Adalimumab) | 65 |
| Benepali® (Etanercept) | 653 |
| Cimzia® (Certolizumab) | 908 |
| Enbrel® (Etanercept) | 2860 |
| Erelzi® (Etanercept) | 234 |
| Flixabi® (Infliximab) | 3 |
| Hulio® (Adalimumab) | 19 |
| Humira® (Adalimumab) | 2905 |
| Hyrimoz® (Adalimumab) | 48 |
| Idacio® (Adalimumab) | 2 |
| Imraldi® (Adalimumab) | 68 |
| Inflectra™ (Infliximab) | 16 |
| Kevzara® (Sarilumab) | 117 |
| Kineret® (Anakinra) | 89 |
| MabThera® (Rituximab) | 1459 |
| Olumiant® (Baricitinib) | 355 |
| Orencia® (Abatacept) | 807 |
| Remicade® (Infliximab) | 762 |
| Remsima® (Infliximab) | 11 |
| Rixathon® (Rituximab) | 9 |
| RoActemra® (Tocilizumab) | 1326 |
| Simponi® (Golimumab) | 444 |
| Xeljanz® (Tofacitinib) | 277 |
| Zessly® (Infliximab) | 2 |
| Kontrollen | 5808 |
Update: August 1st, 2018; enrolled patients: 17,522
| Benepali® (Etanercept) | 447 |
| Cimzia® (Certolizumab) | 841 |
| Enbrel® (Etanercept) | 2859 |
| Erelzi® (Etanercept) | 65 |
| Flixabi® (Infliximab) | 1 |
| Humira® (Adalimumab) | 2883 |
| Inflectra® (Infliximab) | 16 |
| Kevzara® (Sarilumab) | 20 |
| Kineret® (Anakinra) | 89 |
| MabThera® (Rituximab) | 1459 |
| Olumiant® (Baricitinib) | 167 |
| Orencia® (Abatacept) | 718 |
| Remicade® (Infliximab) | 762 |
| Remsima® (Infliximab) | 9 |
| RoActemra® (Tocilizumab) | 1260 |
| Simponi® (Golimumab) | 428 |
| Xeljanz® (Tofacitinib) | 106 |
| Control Group | 5392 |